"Novartis and Voyager Therapeutics Forge $1.2 Billion Neurologic Gene Therapy Alliance"
TL;DR
Novartis has expanded its gene therapy collaboration with Voyager Therapeutics, investing $100 million upfront to acquire capsids targeting Huntington’s disease and spinal muscular atrophy. The announcement, which comes ahead of the JP Morgan Healthcare Conference, has already positively impacted Voyager's stock, with shares increasing by 32%. Additionally, Novartis will purchase $20 million in Voyager shares, further cementing the partnership between the two companies in the field of neurologic gene therapies.
Topics:businessbusinesshealth##businesshealth#genetherapy#healthcareinvestment#neurologicdiseases#novartis#voyagertherapeutics
- Novartis doubles down on neurologic gene therapy work with Voyager Endpoints News
- Voyager Therapeutics shares jump after $1.2 billion deal with Novartis Yahoo Finance
- VYGR Stock Catapults Higher After Novartis Sweetens Its Gene Therapy Deal Investor's Business Daily
- Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies GlobeNewswire
- Novartis signs gene therapy deal with Voyager for $100 mln upfront Reuters
Want the full story? Read the original reporting
Read on Endpoints News